Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17368809 | 0.91 | PLA2G4A (0.61) | PLA2G4AMAPTMMP1MMP13RAB9A | |
| SCHEMBL1667463 | 0.85 | PLA2G4A (0.62) | PLA2G4AMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL12548644 | 0.81 | CES1 (0.56) | PLA2G4ACES1FAAHDAGLA | |
| SCHEMBL12548449 | 0.78 | PLA2G4A (0.59) | PLA2G4AMMP1MMP13CES1FAAH | |
| SCHEMBL1667502 | 0.76 | ALDH1A1 (0.48) | MAPTLMNA | |
| SCHEMBL20662520 | 0.73 | PLA2G4A (0.68) | PLA2G4AMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL17368814 | 0.72 | DAGLA (0.69) | CES1DAGLA | |
| SCHEMBL1667122 | 0.72 | PLA2G4A (0.71) | PLA2G4AMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL20814646 | 0.71 | PLA2G4A (1.00) | PLA2G4AMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1667949 | 0.71 | PLA2G4A (0.64) | PLA2G4AMAPTCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2022-11-17 | — | — | US | disclosed |
| US-11034666-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2021-06-15 | — | — | US | disclosed |
| US-20200299256-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034666-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | CASP1, OXER1, IL1B | PLA2G4A 1499/4885MAPT 2758/4885MMP1 999/4885 |
| US-20200299256-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | CASP1, OXER1, IL1B | PLA2G4A 1553/4885MAPT 2723/4885MMP1 986/4885 |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | OXER1, CASP1, IL6 | PLA2G4A 1539/4885MAPT 2883/4885MMP1 1017/4885 |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | CASP1, IL1B, OXER1 | PLA2G4A 1579/4885MAPT 2844/4885MMP1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.